Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-ranging study of Dysport for painful hip spasticity in children and young people with cerebral palsy
2005-001794-10Phase 4Terminated
- Sponsor
- Ipsen
- Start
- Feb 2006
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of botulinum toxin type A in cerebral palsy (CP) (3 arms), sponsored by Ipsen. Primary endpoints: Change in Paediatric Pain Profile score at Week 4 and Responder rate at Week 4. Started Feb 2006; status: terminated.
02
Drugs
botulinum toxin type A
03
Conditions
cerebral palsy (CP)
Beyond the preview
Go deeper on 2005-001794-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001794-10.